Initiate clinical trial for 3-Gen ETB targeting PD-L1
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- July 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“FPI with 3 -Gen ETB targeting PD-L1 in 1H21.”
What we found
Evidence strength A What the grades mean
The company committed to initiating a clinical trial for its PD-L1 targeting ETB in the first half of 2021, but the study was initiated in July 2021.
-
A Molecular Templates, Inc. 10-Q filed 2021-11-15
“A Phase 1 study of MT-6402 in PD-1/PD-L1 antibody relapsed/refractory patients was initiated in July 2021.” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- 3-Gen ETB targeting PD-L1 clinical trial
- Language
- Aspirational (“aims”, “intends”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Molecular Templates, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C183765-021260 · Corrections policy